Protection against β adrenoceptor agonist reduction of plasma potassium in severe but not in moderate hypokalemia

Fundamental and Clinical Pharmacology

Volumn 25, Issue 4, 2011, Pages 452-461

  Tran, Cao Thach ^a,b   Kjeldsen, Keld ^a,b  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

adrenoceptor agonist; Arrhythmia; Hypokalemia; Na,K ATPase; Potassium; Terbutalin

Indexed keywords

INSULIN; POTASSIUM; POTASSIUM CHLORIDE; SODIUM; TERBUTALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART ARRHYTHMIA; HYPOKALEMIA; MUSCLE LEVEL; NONHUMAN; POTASSIUM BLOOD LEVEL; POTASSIUM DEPLETION; PRIORITY JOURNAL; RAT; RISK REDUCTION; WEIGHT;

ADRENERGIC BETA-AGONISTS; ANIMALS; BLOOD; FEMALE; HEART; HYPOKALEMIA; INSULIN; MUSCLE, SKELETAL; MYOCARDIUM; POTASSIUM; POTASSIUM CHLORIDE; POTASSIUM DEFICIENCY; POTASSIUM, DIETARY; RATS; RATS, WISTAR; TERBUTALINE;

EID: 79959922313     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00937.x     Document Type: Article

References (50)

1. Gennari F.J. Hypokalemia. N. Engl. J. Med. (1998) 339 451-458.
2. Hulting J. In-hospital ventricular fibrillation and its relation to serum potassium. Acta. Med. Scand. Suppl. (1981) 647 109-116.
3. Nordrehaug J.E., Johannessen K.A., von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. Circulation (1985) 71 645-649.
4. Macdonald J.E., Struthers A.D. What is the optimal serum potassium level in cardiovascular patients? J. Am. Coll. Cardiol. (2004) 43 155-161.
5. Tran C.T., Schmidt T.A., Christensen J.B., Kjeldsen K. Atrial Na, K-ATPase increase and potassium dysregulation accentuate the risk of postoperative atrial fibrillation. Cardiology (2009) 114 1-7.
6. Paltiel O., Salakhov E., Ronen I., Berg D., Israeli A. Management of severe hypokalemia in hospitalized patients: a study of quality of care based on computerized databases. Arch. Intern. Med. (2001) 161 1089-1095.
7. Clausen T., Kohn P.G. The effect of insulin on the transport of sodium and potassium in rat soleus muscle. J. Physiol. (1977) 265 19-42.
8. Clausen T., Flatman J.A. The effect of catecholamines on Na-K transport and membrane potential in rat soleus muscle. J. Physiol. (1977) 270 383-414.
9. Buchanan R., Nielsen O.B., Clausen T. Excitation- and beta(2)-agonist-induced activation of the Na(+)-K(+) pump in rat soleus muscle. J. Physiol. (2002) 545 229-240.
10. Nordrehaug J.E., Johannessen K.A., von der Lippe G., Myking O.L. Circulating catecholamine and potassium concentrations early in acute myocardial infarction: effect of intervention with timolol. Am. Heart J. (1985) 110 944-948.
11. van den Berg B.T., Louwerse R.T., Luiken G.J., Jonkers R.E., van Boxtel C.J. Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol. Clin. Drug Investig. (1998) 15 523-529.
12. Habashy D., Lam L.T., Browne G.J. The administration of beta2-agonists for paediatric asthma and its adverse reaction in Australian and New Zealand emergency departments: a cross-sectional survey. Eur. J. Emerg. Med. (2003) 10 219-224.
13. Cazzola M., Imperatore F., Salzillo A. et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest (1998) 114 411-415.
14. Cazzola M., Matera M.G. Safety of long-acting beta2-agonists in the treatment of asthma. Ther. Adv. Respir. Dis. (2007) 1 35-46.
15. McKenna M.J. The roles of ionic processes in muscular fatigue during intense exercise. Sports Med. (1992) 13 134-145.
16. Gullestad L., Hallen J., Sejersted O.M. K+ balance of the quadriceps muscle during dynamic exercise with and without beta-adrenoceptor blockade. J. Appl. Physiol. (1995) 78 513-523.
17. Sejersted O.M., Sjogaard G. Dynamics and consequences of potassium shifts in skeletal muscle and heart during exercise. Physiol. Rev. (2000) 80 1411-1481.
18. Norgaard A., Kjeldsen K., Clausen T. Potassium depletion decreases the number of 3H-ouabain binding sites and the active Na-K transport in skeletal muscle. Nature (1981) 293 739-741.
19. Kjeldsen K., Norgaard A., Clausen T. Effect of K-depletion on 3H-ouabain binding and Na-K-contents in mammalian skeletal muscle. Acta Physiol. Scand. (1984) 122 103-117.
20. Dorup I., Skajaa K., Clausen T., Kjeldsen K. Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics. Br. Med. J. (Clin. Res. Ed) (1988) 296 455-458.
21. Norgaard A., Kjeldsen K., Hansen O. K+-dependent 3-O-methylfluorescein phosphatase activity in crude homogenate of rodent heart ventricle: effect of K+ depletion and changes in thyroid status. Eur. J. Pharmacol. (1985) 113 373-382.
22. Bundgaard H., Kjeldsen K. Potassium depletion increases potassium clearance capacity in skeletal muscles in vivo during acute repletion. Am. J. Physiol. Cell Physiol. (2002) 283 C1163-C1170.
23. Ackerman M.J., Clapham D.E. Ion channels - basic science and clinical disease. N. Engl. J. Med. (1997) 336 1575-1586.
24. Choi C.S., Thompson C.B., Leong P.K., McDonough A.A., Youn J.H. Short-term K(+) deprivation provokes insulin resistance of cellular K(+) uptake revealed with the K(+) clamp. Am. J. Physiol. Renal. Physiol. (2001) 280 F95-F102.
25. Kjeldsen K. Complete quantification of the total concentration of rat skeletal-muscle Na+ + K+-dependent ATPase by measurements of [3H]ouabain binding. Biochem. J. (1986) 240 725-730.
26. Larsen J.S., Kjeldsen K. Quantification in crude homogenates of rat myocardial Na+, K(+)- and Ca(2+)-ATPase by K+ and Ca(2+)-dependent pNPPase. Age-dependent changes. Basic Res. Cardiol. (1995) 90 323-331.
27. Chen P., Guzman J.P., Leong P.K. et al. Modest dietary K+ restriction provokes insulin resistance of cellular K+ uptake and phosphorylation of renal outer medulla K+ channel without fall in plasma K+ concentration. Am. J. Physiol. Cell Physiol. (2006) 290 C1355-C1363.
28. Hurlbert B.J., Edelman J.D., David K. Serum potassium levels during and after terbutaline. Anesth. Analg. (1981) 60 723-725.
29. Epstein F.H., Rosa R.M. Adrenergic control of serum potassium. N. Engl. J. Med. (1983) 309 1450-1451.
30. Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundam. Clin. Pharmacol. (2010) 24 595-605.
31. Ahmed A., Zannad F., Love T.E. et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur. Heart J. (2007) 28 1334-1343.
32. Bowling C.B., Pitt B., Ahmed M.I. et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ. Heart Fail. (2010) 3 253-260.
33. Korgaonkar S., Tilea A., Gillespie B.W. et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin. J. Am. Soc. Nephrol. (2010) 5 762-769.
34. Ahmed M.I., Ekundayo O.J., Mujib M. et al. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int. J. Cardiol. (2010) 144 383-388.
35. Hunt S.A., Abraham W.T., Chin M.H. et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation (2009) 119 e391-e479.
36. Hallen J., Saltin B., Sejersted O.M. K+ balance during exercise and role of beta-adrenergic stimulation. Am. J. Physiol. (1996) 270 R1347-R1354.
37. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest (2004) 125 2309-2321.
38. Allon M., Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. (1990) 38 869-872.
39. Clausen T. Na+-K+ pump regulation and skeletal muscle contractility. Physiol. Rev. (2003) 83 1269-1324.
40. Clausen T. Clearance of extracellular K+ during muscle contraction - roles of membrane transport and diffusion. J. Gen. Physiol. (2008) 131 473-481.
41. Nakao M., Gadsby D.C. [Na] and [K] dependence of the Na/K pump current-voltage relationship in guinea pig ventricular myocytes. J. Gen. Physiol. (1989) 94 539-565.
42. Adamopoulos C., Pitt B., Sui X., Love T.E., Zannad F., Ahmed A. Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int. J. Cardiol. (2009) 136 270-277.
43. Cleland J.G., Dargie H.J., Ford I. Mortality in heart failure: clinical variables of prognostic value. Br. Heart J. (1987) 58 572-582.
44. Yusuf S., Pfeffer M.A., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 362 777-781.
45. Pedersen G., Pedersen A., Pedersen E.B. Effect of propranolol on total exchangeable body potassium and total exchangeable body sodium in essential hypertension. Scand. J. Clin. Lab. Invest. (1979) 39 167-170.
46. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341 709-717.
47. Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. (2011) 364 11-21.
48. Ahmed A., Pitt B., Rahimtoola S.H. et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int. J. Cardiol. (2008) 123 138-146.
49. The Digitalis Investigation Group [No authors listed]. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. (1997) 336 525-533.
50. Ekundayo O.J., Adamopoulos C., Ahmed M.I. et al. Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int. J. Cardiol. (2010) 141 167-174.